CN104673799B - It targets the siRNA of people RAN and its is preparing the purposes in anti-viral hepatitis type C drug - Google Patents
It targets the siRNA of people RAN and its is preparing the purposes in anti-viral hepatitis type C drug Download PDFInfo
- Publication number
- CN104673799B CN104673799B CN201510102905.4A CN201510102905A CN104673799B CN 104673799 B CN104673799 B CN 104673799B CN 201510102905 A CN201510102905 A CN 201510102905A CN 104673799 B CN104673799 B CN 104673799B
- Authority
- CN
- China
- Prior art keywords
- ran
- sirna
- sequence
- cell
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to pharmaceutical technology fields, more particularly to siRNA, especially one kind are directed to the siRNA of RAN (Ras-related nuclear protein) gene target and its are preparing the purposes in 2 type viral hepatitis type C drug of therapeutic gene.Target the siRNA of people RAN: the sequence of positive-sense strand are as follows: ACAGGAAAGUGAAGGCGAA dTdT, the sequence of antisense strand are as follows: dTdT UGUCCUUUCACUUCCGCUU.The present invention, which is experimentally confirmed, transfects Huh7.5.1 cell for the siRNA interference sequence 003 for targeting people RAN, makes RAN silenced gene expression therein, and then can inhibit karyon-cytoplasm indexing of PTB, to play HCV-Ab IgG effect.Therefore the siRNA interference sequence 003 of RAN can be prepared into drug as active constituent, the treatment for viral hepatitis type C using RAN as molecular target.
Description
Technical field
The present invention relates to pharmaceutical technology field more particularly to siRNAs, especially a kind of to be directed to RAN (Ras-
Related nuclear protein) gene target siRNA and its preparing the 2 viral liver of the third type of type of therapeutic gene
Purposes in scorching drug.
Background technique
Hepatitis C Virus (Hepatitis C Virus, HCV) infection can cause urgency/chronic hepatitis, cirrhosis and liver
Cancer.There are about 1.85 hundred million HCV infection persons, infection rate is about 1-2% in the whole world at present, and the infection rate of East Asia Region is the 3.7% (world
Health organization hepatitis practice guidelines in 2014).Annual new infections person exceedes 3,000,000, especially the most serious with developing country.Every year
There are about 500,000 HCV infection persons death.Existing treatment is only capable of making about 50% patient to obtain continued viral response (SVR), and exists
The problems such as using taboo, individual difference and drug side-effect.There are no HCV preventative vaccines in the whole world so far, cannot block
The propagation of HCV.Therefore, hepatitis is still the Important Infectious Diseases for threatening human health within considerable time from now on, it would be highly desirable to be opened
The new safely and effectively alternative medicine of hair.
HCV infection cell model be successfully established to small molecule compound inhibit HCV duplication research development played it is huge
Big effect.Currently, being usually used in constructing clone's system of HCV Infection in Vitro model being JFH1 plants.Common culture cell is people liver
Cancer cell line Huh7 and its derived cell system Huh7.5 and Huh7.5.1.The chimeric strain of the HCV 2a JFH1 and J6 that then construct
PFL-JC1 confirms there is higher duplicating efficiency than JFH1 plants.These model systems allow to assess antiviral drugs to HCV RNA
Duplication, viral generation and infective influence, therefore also contribute to the fast development of anti-HCV medicament.
RNA interferes (RNA interference, RNAi) by causing posttranscriptional gene silencing in conjunction with specific mrna
Or target mRNA degradation.An independent technology is had become at present, and action target spot specificity is high, small to cytotoxicity, pacifies relatively
Entirely, cause the broad interest of the nearly all research field in biomedical boundary.First item clinical test is by Acuity
The siRNA that VEGF is targeted for treating age-related macular degeneration (AMD) that Pharmaceuticals company will develop in the end of the year 2004.
It is Calando company for treating the CALAA01 of entity tumor that siRNA, which acts on the first clinical research of cancer, in
It obtains FDA approval in May, 2008 and enters I phase clinic.
RAN (Ras related nucleoprotein) is also referred to as GTP combination nucleoprotein, is a member of Ras superfamily.RAN is RNA
It is transported with protein by nuclear pore complex essential, also assists in control DNA synthesis and cell cycle progression.It has been found that
RAN gene mutation can destroy the synthesis of DNA.During mitosis, mitosis is spun after RAN circulation participates in chromosome separation
Hammer body assembling and nuclear membrane recombination.RAN or the androgen receptor co-activation factor, can be with the poly glumine of different length in hero
Hormone receptor difference combines.
Summary of the invention
The purpose of the present invention is to provide a kind of siRNAs and application thereof for people's RAN gene target.
Target the siRNA of people RAN:
The sequence of positive-sense strand are as follows: ACAGGAAAGUGAAGGCGAA dTdT
The sequence of antisense strand are as follows: dTdT UGUCCUUUCACUUCCGCUU
Target purposes of the siRNA of people RAN in the drug for preparing HCV-Ab IgG infection.
The siRNA of targeting people RAN is preparing the purposes in 2 type viral hepatitis type C drug of therapeutic gene.
A method of inhibit PTB to be indexed into cytoplasm by karyon, the siRNA for targeting people RAN is transfected into Huh7.5.1
Cell, makes the expression silencing of RAN, and karyon-cytoplasm indexing of PTB is inhibited.
The present invention, which is experimentally confirmed, transfects Huh7.5.1 cell for the siRNA interference sequence 003 for targeting people RAN, makes it
In RAN silenced gene expression, and then the karyon of PTB-cytoplasm indexing can be inhibited, to play HCV-Ab IgG effect.It therefore can be with
Using RAN as molecular target, the siRNA interference sequence 003 of RAN is prepared into drug as active constituent, for the third type virus
The treatment of property hepatitis.
Detailed description of the invention
Fig. 1 is Q-PCR and western blot experimental result, to analyse HCV infection to RAN from mRNA and protein level
The influence of expression.
Fig. 2 is western blot experiment, and to prove the interference effect of RAN from protein level, wherein NC is indicated unrelated
Sequence, 003,004 and 005 is RAN interference sequence.Particular sequence is as follows:
The sequence of 003 positive-sense strand are as follows: ACAGGAAAGU GAAGGCGAA dTdT
The sequence of 003 antisense strand are as follows: dTdT UGUCCU UUCACUUCCGCUU
The sequence of 004 positive-sense strand are as follows: GACCUUCGUGAAACGUCAU dTdT
The sequence of 004 antisense strand are as follows: dTdT CUGGAAGCACUUUGCAGUA
The sequence of 005 positive-sense strand are as follows: GUAUGUAGCCACCUUGGGU dTdT
The sequence of 005 antisense strand are as follows: dTdT CAUACAUCGGUGGAACCCA
Behind Huh7.5.1 cell 48 hours of 003 interference JC1 infection of Fig. 3 western blot experiment display, HCV Core
Protein level significantly reduces.
Behind Huh7.5.1 cell 48 hours of 003 interference JC1 infection of Fig. 4 western blot experiment display, PTB albumen
Cytoplasm-karyon indexing is reduced.
Specific embodiment
In order to make it easy to understand, the present invention will be described in detail by specific drawings and examples below.It needs
It is emphasized that specific example and attached drawing are merely to explanation, it is clear that those skilled in the art can be according to herein
Illustrate, various modifications and variations are made to the present invention within the scope of the invention, these modifications and variations are also included in this
In the range of invention.
Method therefor is conventional method unless otherwise instructed in the following example.Required material in following embodiment
Material or reagent, are that market is bought unless otherwise specified.
RAN expression is analyzed after 1 JC1 of embodiment infection
The foundation of HCV cell infection model
First 1 day of transfection, with 1 × 107A/hole density is inoculated with 10cm culture dish, and cell fusion degree is 70%~80%.Transfection
When, 10 μ g HCV RNA transcriptions are taken, imported into support in the method for 260V and 25 millisecond pulse length folk prescription wave electrotransfections
The liver cancer cell lines Huh7.5.1 of HCV duplication.Cell conditioned medium is collected, 1500g centrifugation 5min removal cell fragment is placed on -70 DEG C
It saves.Again plantation Huh7.5.1 cell is in six porocyte culture plates, and when cell is up to 50%~60% degrees of fusion, every hole is added
The cell conditioned medium that 2ml is collected is cleaned three times after being incubated for 24 hours with PBS, and complete medium is added and continues to cultivate.It is received after 48 hours
Collect cell and carries out subsequent experimental.
Quantitative fluorescent PCR
Utilize the intracellular HCV RNA relative quantity of fluorescence quantitative PCR detection.Cell is collected after pancreatin digestion, every pipe is added
Trizol extracts total serum IgE according to operating instruction, and ultraviolet specrophotometer measures concentration.Take 4 μ l RNA according to Reverse Transcriptase kit
Operating instruction first removes genomic DNA, then carries out reverse transcription reaction, and reaction system is 20 μ l.The cDNA of synthesis is as real-time
Quantitative PCR template, positive antisense primer of the reaction system including 2 × SYBR Green Taq reaction solution, 10 μ l, HCV or GAPDH are each
0.4 μ l, 0.4 μ l of Rox II, 6.8 μ l and cDNA template of sterile purified water, 22 μ l.PCR reaction condition is 95 DEG C of 30s；95 DEG C of 5s,
60 DEG C of 30s, totally 40 recycle.For detecting the primer of RAN, upstream: 5 '-GTGAAGGCGAAATCCATTGT-3 ', downstream:
5'-TCCTAGCAAGCCAGAGGAAG-3'；Reference gene glyceraldehyde 3-phosphate dehydro-genase (GAPDH) amplimer, upstream:
5 '-GAAGGTGAAGGTCGGAGTC-3 ', downstream: 5 '-GAAGATGGTGATGGGATTTC-3 '.All samples target gene phase
Expression is calculated after reference gene GAPDH homogenization processing.
Western Blot detection
Western Blot detects HCV Core and RAN protein expression level.Extract total protein of cell and according to BCA albumen
The operating instruction of quantification kit carries out quantitative analysis.Above-mentioned 40 μ g of total protein of cell is taken to separate and be transferred to using SDS-PAGE
On nitrocellulose filter.After the closing of 5% skimmed milk power, by film and antibody HCV Core (Abcam), RAN (Abcam) and β-
4 DEG C of actin (Cell signaling Technology) overnight incubations, secondary antibody use chemical illuminating reagent after being incubated for 1 hour
(Pierce) it detects.
It is increased as shown in Figure 1, HCV infection can induce RAN expression.
The screening of 2 RAN interference sequence of embodiment
RNA interference
First 1 day of transfection, with 2 × 105A/hole density is inoculated with 6 porocyte culture plates.When transfection, 10 μ l siRNA (commission is taken
Sharp rich biosynthesis) it is diluted in 100 μ l Opti-MEM I serum free mediums, it mixes gently；Take 2 μ l
LipofectamineTMRNAiMAX is diluted in 100 μ l Opti-MEM I serum free mediums, is mixed gently.It will be diluted
HCV RNA and LipofectamineTMRNAiMAX is gently mixed, and is stored at room temperature 20min.6 orifice plates are added in 200 μ l compounds
In cell, mix gently.2mlJC1 viral supernatants infection cell is added in every hole after 24 hours, and training completely is added after being incubated for 24 hours
Feeding base continues to cultivate.Cell is collected after 48 hours carries out subsequent experimental.
Quantitative fluorescent PCR
Utilize the intracellular HCV RNA relative quantity of fluorescence quantitative PCR detection.Cell is collected after pancreatin digestion, every pipe is added
Trizol extracts total serum IgE according to operating instruction, and ultraviolet specrophotometer measures concentration.Take 4 μ l RNA according to Reverse Transcriptase kit
Operating instruction first removes genomic DNA, then carries out reverse transcription reaction, and reaction system is 20 μ l.The cDNA of synthesis is as real-time
Quantitative PCR template, positive antisense primer of the reaction system including 2 × SYBR Green Taq reaction solution, 10 μ l, HCV or GAPDH are each
0.4 μ l, 0.4 μ l of Rox II, 6.8 μ l and cDNA template of sterile purified water, 22 μ l.PCR reaction condition is 95 DEG C of 30s；95 DEG C of 5s,
60 DEG C of 30s, totally 40 recycle.For detecting the primer of RAN, upstream: 5 '-GTGAAGGCGAAATCCATTGT-3 ', downstream:
5'-TCCTAGCAAGCCAGAGGAAG-3'；Reference gene glyceraldehyde 3-phosphate dehydro-genase (GAPDH) amplimer, upstream:
5 '-GAAGGTGAAGGTCGGAGTC-3 ', downstream: 5 '-GAAGATGGTGATGGGATTTC-3 '.All samples target gene phase
Expression is calculated after reference gene GAPDH homogenization processing.
Western Blot detection
Western Blot detects RAN protein expression level.Extract total protein of cell and according to BCA protein quantification kit
Operating instruction carry out quantitative analysis.Above-mentioned 40 μ g of total protein of cell is taken to separate using SDS-PAGE and be transferred to nitrocellulose
On film.After the closing of 5% skimmed milk power, by film and antibody RAN (Abcam) and β-actin (Cell signaling
Technology) 4 DEG C of overnight incubations, secondary antibody are detected after being incubated for 1 hour with chemical illuminating reagent (Pierce).
As shown in Fig. 2, 003 interference effect of RAN interference sequence is the most significant.
3 003 HCV-Ab IgG effect analysis of embodiment
Western Blot detection
Western Blot detects HCV Core Protein expression.Total protein of cell is extracted after RNA interference and according to BCA
The operating instruction of protein quantification kit carries out quantitative analysis.Above-mentioned 40 μ g of total protein of cell is taken to separate and turn using SDS-PAGE
It moves on on nitrocellulose filter.After the closing of 5% skimmed milk power, by film and antibody HCV Core (Abcam) and β-actin (Cell
Signaling Technology) 4 DEG C be incubated overnight, secondary antibody is detected after being incubated for 1 hour with chemical illuminating reagent (Pierce).
As shown in figure 3,003 can significantly inhibit HCV Core Protein expression.
4 003 HCV-Ab IgG mechanism analysis of embodiment
Western Blot detection
Western Blot detection PTB albumen is indexed into the level of cytoplasm by karyon.Total protein of cell is extracted after RNA interference
And quantitative analysis is carried out according to the operating instruction of BCA protein quantification kit.Above-mentioned 40 μ g of total protein of cell is taken to use SDS-
PAGE is separated and is transferred on nitrocellulose filter.After the closing of 5% skimmed milk power, by film and antibody PTB (Abcam), β-actin
4 DEG C of (Cell signaling Technology) and PCNA (Cell signaling Technology) overnight incubations, secondary antibody
It is detected after being incubated for 1 hour with chemical illuminating reagent (Pierce).
As shown in figure 4,003 can significantly inhibit PTB albumen and be indexed into cytoplasm by karyon
HCV-Ab IgG effect can be played by inhibiting PTB albumen to be indexed into cytoplasm by karyon by showing 003 based on the above results.
Claims (1)
1. purposes of the siRNA of following sequence in the drug for preparing HCV-Ab IgG infection, siRNA inhibits HCV duplication；
The sequence of the positive-sense strand of siRNA are as follows: ACAGGAAAGUGAAGGCGAA dTdT；
The sequence of the antisense strand of siRNA are as follows: dTdT UGUCCUUUCACUUCCGCUU.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510102905.4A CN104673799B (en) | 2015-03-09 | 2015-03-09 | It targets the siRNA of people RAN and its is preparing the purposes in anti-viral hepatitis type C drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510102905.4A CN104673799B (en) | 2015-03-09 | 2015-03-09 | It targets the siRNA of people RAN and its is preparing the purposes in anti-viral hepatitis type C drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104673799A CN104673799A (en) | 2015-06-03 |
| CN104673799B true CN104673799B (en) | 2019-02-05 |
Family
ID=53309389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510102905.4A Expired - Fee Related CN104673799B (en) | 2015-03-09 | 2015-03-09 | It targets the siRNA of people RAN and its is preparing the purposes in anti-viral hepatitis type C drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104673799B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608706B2 (en) * | 2002-11-14 | 2009-10-27 | Dharmacon, Inc. | siRNA targeting ras-related nuclear protein |
-
2015
- 2015-03-09 CN CN201510102905.4A patent/CN104673799B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608706B2 (en) * | 2002-11-14 | 2009-10-27 | Dharmacon, Inc. | siRNA targeting ras-related nuclear protein |
Non-Patent Citations (3)
| Title |
|---|
| RAN siRNA对辐射诱发基因组不稳定肝细胞凋亡及细胞周期的影响;党旭红,等;《中国药理学与毒理学杂志》;20131130;第27卷;摘要 |
| siRNA 抑制丙型肝炎病毒IRES 介导的基因表达;饶林，等;《中国生物化学与分子生物学报》;20040229;第20卷(第1期);38-43 |
| 小G蛋白Ran对胰腺癌细胞增殖和凋亡的调控;邓林 等;《现代生物医学进展》;20130228;第13卷(第4期);658页左栏第一段 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104673799A (en) | 2015-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leggio et al. | microRNAs in Parkinson’s disease: from pathogenesis to novel diagnostic and therapeutic approaches | |
| CN101603042B (en) | RNA interference target for treating hepatitis B virus infection | |
| Jadhav et al. | HIV‐1 Tat C modulates NOX 2 and NOX 4 expressions through miR‐17 in a human microglial cell line | |
| Gupta et al. | MicroRNAs, hepatitis C virus, and HCV/HIV-1 co-infection: new insights in pathogenesis and therapy | |
| Panda et al. | MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies | |
| Fornari et al. | MicroRNAs in animal models of HCC | |
| CN107893078B (en) | SiRNA (small interfering ribonucleic acid) of targeted synaptotagmin-11, expression vector and virus particle and pharmaceutical application thereof | |
| Zhang et al. | miR-27a suppresses EV71 replication by directly targeting EGFR | |
| Zhao et al. | miR-27b attenuates apoptosis induced by transmissible gastroenteritis virus (TGEV) infection via targeting runt-related transcription factor 1 (RUNX1) | |
| EP3189856B1 (en) | Method for inhibiting ebola virus via mirna | |
| Ye et al. | Hepatitis B virus therapeutic agent ARB-1740 has inhibitory effect on hepatitis delta virus in a new dually-infected humanized mouse model | |
| Unfried et al. | The landscape of lncRNAs in hepatocellular carcinoma: a translational perspective | |
| Mori et al. | Induction of selective autophagy in cells replicating hepatitis C virus genome | |
| Barrey et al. | Think different with RNA therapy: can antisense oligonucleotides be used to inhibit replication and transcription of SARS-CoV-2? | |
| Carnero et al. | HCV infection, IFN response and the coding and non-coding host cell genome | |
| CN105063044A (en) | Active molecule capable of suppressing gene replication of Ebola virus and usage method thereof | |
| Abdullah et al. | The DDX23 negatively regulates translation and replication of foot-and-mouth disease virus and is degraded by 3C proteinase | |
| Ye et al. | MiR-103a-3p promotes Zika virus replication by targeting OTU Deubiquitinase 4 to activate p38 mitogen-activated protein kinase signaling pathway | |
| Raimondi et al. | Inhibition of miR-222 by oncolytic adenovirus-encoded miRNA sponges promotes viral oncolysis and elicits antitumor effects in pancreatic cancer models | |
| CN104673799B (en) | It targets the siRNA of people RAN and its is preparing the purposes in anti-viral hepatitis type C drug | |
| Cousineau et al. | Poly (rC)-binding protein 1 limits hepatitis C virus virion assembly and secretion | |
| Qian et al. | Hepatitis C Virus Infection Cycle-Specific MicroRNA Profiling Reveals Stage-Specific miR-4423-3p Targets RIG-I to Facilitate Infection | |
| Huang et al. | Downregulation of miR-26b attenuates early brain injury induced by subarachnoid hemorrhage via mediating the KLF4/STAT3/HMGB1 axis | |
| Wang et al. | G-quadruplex in hepatitis B virus pregenomic RNA promotes its translation | |
| Wang et al. | MiR-29c inhibits HCV replication via activation of type I IFN response by targeting STAT3 in JFH-1-infected Huh7 cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190205 Termination date: 20200309 |